A press conference and deepening cooperation signing ceremony between Lisen Imprinting and Galixir was held in Shanghai on November 1, 2021. Also present were representatives from Shanghai Zhangjiang Medicine Public Service Platform and Merck China Innovation Center who graced the occasion with congratulatory messages and motivational speeches. Well-known investment institutions such as Baida Finance, BAI […]
Read More
Lisen announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection. The clinical research was published in the Clinical Epigenetics on December 14. The new diagnostic method was based on the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology developed by Lisen, which can intuitively translate the biallelic and multiallelic expression status of cancer-related […]
Read More